Navigation Links
CytoGenix Announces Successful Testing of synDNA Vaccine for Avian,Influenza Virus

HOUSTON--(BUSINESS WIRE)--Apr 4, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that it has successfully completed an important pilot study with a novel synDNA(TM) vaccine designed for humans (therapeutic) and intended to protect against the avian (H5N1) influenza virus. The study clearly demonstrated a robust protective effect in mice treated with the Company's synDNA(TM) vaccine whereas all the untreated control animals died after both groups were challenged with a highly virulent strain of avian influenza virus (Vietnam/1203/04). The lethal challenge testing was conducted by recognized collaborators in the field under a sponsored research agreement with the Company.

The complete results from this study and related tests of synDNA(TM) vaccines will be presented at the 2007 DNA Vaccine conference to be held 23-25 May 2007 in Malaga, Spain.

Dr. Yin Chen, Chief Scientific Officer, stated, "This novel DNA vaccine was produced using a unique combination of novel gene sequences and our proprietary synDNA(TM) production technology. We are extremely excited about this initial robust response in an animal challenge model."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release ar e forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Contact

CytoGenix, Inc., Houston
Media Contact:
Pam Schertz, 713-789-0070


'"/>




Related medicine technology :

1. CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016   , Study ... overall bowel cleansing and superiority in , ... of the ascending colon ... Norgine B.V. today announced new positive data from the ... bowel preparation) versus standard 2 litre PEG with ascorbate. The study ...
(Date:5/24/2016)... N.J. , May 24, 2016 ... oncology drug development company, today provided an update ... dose escalating clinical trial combining GEN-1, the Company,s ... the treatment of newly-diagnosed patients with advanced ovarian ... interval debulking surgery.  GEN-1 is an IL-12 DNA ...
(Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
Breaking Medicine Technology:
(Date:5/25/2016)... York, NY (PRWEB) , ... May 25, 2016 ... ... Medicine and Florida International University (FIU) Herbert Wertheim College of Medicine announced the ... a Medical Doctor Degree and Global Health Certificate from AUA and a Certificate ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Dr. Travis Schwarz ... Plaza at 8618 Mexico Road, O’Fallon, MO 63366. He serves patients of all ages ... cosmetic treatments . Dr. Schwarz’s success is reflected in the superior patient reviews that ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Today Omega ... launch of 11 innovative workshops and training opportunities in the growing field ... unique needs of individuals who are dealing with specific health issues—including injuries, illnesses, and ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker Insurance Group ... Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most successful agencies ... inspire all those who knew him. The award named for him is not given ...
(Date:5/25/2016)... ... 2016 , ... The Global Wellness Summit (GWS) today announced that its 2016 ... Europe, a continent that pioneered the medical/wellness concept for the world. , Delegates to ... wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness centers around ...
Breaking Medicine News(10 mins):